Abstract
Great progress has been made in the last 2 decades since the first successful allogeneic marrow transplants were performed in man. Cure rates approaching 40-60% are possible in acute leukemias and chronic myelogenous leukemia, 50-70% in severe aplastic anemia and 70-80% in beta thalassemia. Data in animal disease models and early clinical results indicate that allogeneic marrow transplantation may assume a role in the therapy of lysosomal storage diseases. It is in these genetic diseases that gene transfer therapy may eventually be tried. Marrow transplantation is now a world wide endeavor. The International Bone Marrow Transplantation Registry estimates that more than 2,500 allogeneic and 1,000 autologous transplants are performed annually.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag New York Inc.
About this paper
Cite this paper
Santos, G.W. (1988). Conclusions. In: Baum, S.J., Santos, G.W., Takaku, F. (eds) Recent Advances and Future Directions in Bone Marrow Transplantation. Experimental Hematology Today—1987, vol 1987. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3762-4_34
Download citation
DOI: https://doi.org/10.1007/978-1-4612-3762-4_34
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-8339-3
Online ISBN: 978-1-4612-3762-4
eBook Packages: Springer Book Archive